Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
International Journal of Molecular Medicine|October 9, 2003
RB1CC1 suppresses cell cycle progression through RB1 expression in human neoplastic cellsKeiichi Kontani, Tokuhiro Chano, Yoshitomo Ozaki, et al.
Anticancer Research|July 3, 2019
Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 AntibodiesKohei Fujita, Naohiro Uchida, Yuki Yamamoto, et al.
Thoracic Cancer|November 9, 2019
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibodyKohei Fujita, Yuki Yamamoto, Osamu Kanai, et al.
NMC Case Report Journal|January 23, 2018
Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage TherapyYasuhiro Kawabata, Tomokazu Aoki, Tetsurou Yamamoto, et al.
Plant Biotechnology (Tokyo, Japan)|March 21, 2025
Disruption of CYP88B1 by transcription activator-like effector nuclease in potato and potential use to produce useful saponinsShuhei Yasumoto, Hyoung Jae Lee, Ryota Akiyama, et al.
The Plant Journal : for Cell and Molecular Biology|October 25, 2016
Draft genome assembly and annotation of Glycyrrhiza uralensis, a medicinal legumeKeiichi Mochida, Tetsuya Sakurai, Hikaru Seki, et al.
Surgery Today|November 22, 2002
Mediastinal cavernous hemangioma in a child: report of a caseJun Hanaoka, Shuhei Inoue, Shozo Fujino, et al.
International Journal of Molecular Medicine|September 10, 2003
Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucinKeiichi Kontani, Osamu Taguchi, Yoshitomo Ozaki, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2012
A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancerKoji Teramoto, Yoshikuni Asada, Yoshitomo Ozaki, et al.
Discover Oncology|August 31, 2023
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodiesTakuma Imakita, Kohei Fujita, Takanori Ito, et al.
Pageof 7